MassDevice.com +5 | The top 5 medtech stories for April 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Star Trek tricorder: This may be the best we can do – for now
They don’t diagnose diseases with a few waves of the hand, the way that Dr. Leonard McCoy would with his tricorder on Star Trek. But 2 mobile platforms – algori...
Source: Mass Device - April 17, 2017 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news
Novocure gains on additional Optune data
Shares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma.
Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication.
Get the full story on our sister site, Drug Delivery Business News.
The post Novocure gains on additional Optune data appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 17, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Oncology Radiosurgery Wall Street Beat NovoCure Source Type: news
Vaccine/Chemotherapy Combination Improves Survival in Glioblastoma
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Brain Tumors News Source Type: news
Glioblastoma patients may benefit from a vaccine-chemotherapy combination
(American Association for Cancer Research) A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2017 Category: Global & Universal Source Type: news
AACR: TTFields + Temozolomide Ups Survival in Glioblastoma
Compliance with TTFields treatment predicts outcome, with better outcome for>18 hour/day (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 3, 2017 Category: Cancer & Oncology Tags: Neurology, Oncology, Conference News, Source Type: news
Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma
Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy for the treatment of newly-diagnosed glioblastoma.
Data from 695 patients show a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, the St. Helier, N.J.-based company said. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication
Get the full story at our sister si...
Source: Mass Device - April 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Wall Street Beat NovoCure Source Type: news
Adding Temozolomide to Short-Course RT Effective in Elderly Glioblastoma
Elderly patients with glioblastoma had longer survival when temozolomide was added to short-course radiotherapy compared with undergoing short-course radiotherapy alone. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Brain Tumors News Radiation Oncology Source Type: news
Chemoradiation Boosts Survival in Elderly Glioblastoma Patients Chemoradiation Boosts Survival in Elderly Glioblastoma Patients
Adding temozolomide to radiotherapy improves survival in elderly glioblastoma patients when compared to radiotherapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Glioblastoma clinical trial shows combined therapy extends life for patients 65 and older
(University Health Network) Treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extends survival by two months compared to treating with radiation alone, show clinical trial results published in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2017 Category: Cancer & Oncology Source Type: news
A new prognostic classification may help clinical decision-making in glioblastoma
(Ohio State University Wexner Medical Center) New research shows that taking molecular variables into account will improve the prognostic classification of the lethal brain cancer called glioblastoma (GBM). Published in the journal JAMA Oncology, the study found that adding significant molecular biomarkers to the existing GBM classification system improves the prognostic classification of GBM patients who have been treated with radiation and the drug temozolomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2017 Category: Cancer & Oncology Source Type: news
NovoCure touts long-term analysis for Optune TTF, drug combo in brain cancer
NovoCure (NSDQ:NVCR) today released long-term analysis data from the phase 3 pivotal EF-14 trial of its Optune device in combination with temozolomide for treating newly diagnosed glioblastoma, touting superior survival results.
Data from the trial indicated superior 2, 3 and 4-year survival rates for patients treated with the combined therapy over temozolomide alone.
Data from the study is slated to be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in Scottsdale, Ariz. this week.
“The long-term analysis further supports our data showing that Optune together with temozolomide is a ...
Source: Mass Device - November 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news
Ibudilast Plus Temozolomide Shows Preclinical Promise in Glioblastoma
The anti-inflammatory ibudilast shows early preclinical promise against glioblastoma cell lines when combined with temozolomide, according to research presented at the 2016 SNO Scientific Meeting. (Source: CancerNetwork)
Source: CancerNetwork - November 18, 2016 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Brain Tumors News Conferences/SNO 2016 Source Type: news
Novocure touts long-term analysis of Optune drug-device combo
Novocure (NSDQ: NVCR) touted a long-term analysis of data from a Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-formed glioblastomas.
Survival data for nearly 700 patients confirmed interim results from the trial, 1st published in December 2015 in the Journal of the American Medical Assn. Patients treated with Optune plus temozolomide had superior 2-, 3- and 4-year survival rates compared to patients treated with temozolomide alone.
The results come weeks after the St. Helier, N.J.-based company announced that Optune, in combination with placlitaxel, is effective a...
Source: Mass Device - September 12, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Radiosurgery NovoCure Source Type: news
DelMar, Accurexa ink deal for chemotherapy combo
DelMar Pharmaceuticals and Accurexa said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer.
The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable polymer wafer. DelMar said its drug proved successful in more than 40 clinical trials sponsored by the U.S. National Cancer Institute, winning orphan drug designation as a treatment for gliomas, medulloblastoma and ovarian cancer in Apr...
Source: Mass Device - September 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Oncology Pharmaceuticals Research & Development Accurexa Inc. DelMar Pharmaceuticals Source Type: news
New Standard for Older Patients With Glioblastoma
(MedPage Today) -- Radiation plus temozolomide extends survival (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 10, 2016 Category: Geriatrics Source Type: news
